LATEST NEWS | 24th Nov 2021 Anteris Technologies CEO talks 'outstanding results' from first human DurAVR patients

Investor Centre

Investor News

Visit the news page to see the latest news.

Why Invest?

The FDA approval of Transcatheter Aortic Valve Replacement (TAVR) in the treatment of low-risk (younger patients) is driving rapid market expansion. Today we have

The Right Opportunity
to introduce a potential functional cure in the treatment of Aortic Stenosis where hemodynamics are reverted to normal pre-disease status and sustained for the life of the patient.

With TAVR now being the treatment of choice for Aortic Stenosis patients, coupled with existing Transcatheter Heart Valves failing as early as five to eight years after implantation, then now is

The Right Time
for a solution that Works Better & Lasts Longer.

At Anteris we bring

The Right Technology
to patients requiring a replacement valve. DurAVR™ heart valves address both the acute need in terms of superior hemodynamic profile, as well as chronic needs in their ability to sustain that profile longer, over the lifetime of the patient.

The inspiration for our DurAVR™ heart valves* stemmed from multiple conversations with interventional cardiologists, who reiterated that valve durability and repeat replacements were posing a large risk to patient health.

The proven benefits of our ADAPT® tissue paired with the unique design of DurAVR™ our 3D single-piece aortic valve, answers the need to

potentially deliver a functional cure
in the treatment of Aortic Stenosis, and provides a much-needed solution to the challenges facing heart surgeons today.

Learn more about
The Right Technology
, visit now ,

At Anteris we are committed in delivering durable solutions through our Better Science & Better Design that help healthcare professionals create life-changing outcomes for patients.

ASX Announcements

  -  
Showing - of
⚑ = Price Sensitive
Subscribe to the ASX Annoucements Feed

Financial Reports

2021
  • 2021 Consolidated Half Year Financial Report
    View
2020
  • 2020 Annual Report
    View
  • 2020 Consolidated Half Year Financial Report
    View
2019
  • 2019 Annual Report
    View
  • 2019 Consolidated Half Year Financial Report
    View
2018
  • 2018 Annual Report
    View
  • 2018 Consolidated Half Year Financial Report
    View
2017
  • 2017 Annual Report (Jul 17 - Dec 17)
    View
  • 2017 Annual Report (Jul 16 - Jun 17)
    View
  • 2017 Consolidated Half Year Financial Report (Jul 16 - Dec 16)
    View
2016
  • 2016 Annual Report
    View
  • 2016 Consolidated Half Year Financial Report
    View
2015
  • 2015 Annual Report
    View
  • 2015 Consolidated Half Year Financial Report
    View

Research Reports

  • 2021 Consolidated Half Year Financial Report
    View
  • MST Access - AVR Update Report - Aug 21
    View
  • MST Access - AVR Update Report - May 21
    View
  • MST Access - Q4 Results: Fresh Funds Available, Trials Progressing Well
    View
  • Bioshares November 2020 Report
    View
  • MST Access - Initiation of Coverage October 2020
    View
  • Bioshares July 2020 Report
    View
  • ABID June 2020 Report
    View
  • Bioshares June 2020 Report
    View
  • NDF Research - ADAPTing to market opportunities
    View

Annual General Meetings

Share Registry

Computershare Investor Services Pty Ltd

Level 1, 200 Mary Street
Brisbane, QLD 4000

T 1300 850 505 (within Australia)
T +61 3 9415 4000 (outside Australia)
F 1800 783 447 (within Australia)
F +61 3 9473 2555 (outside Australia)

ComputerShare Investor Services manages our share registry. You can contact them for details about your holding here.

A copy of our recent top 20 shareholder list is available here.

Contact Us

+61